Petra Kaufmann
Chief Tech/Sci/R&D Officer at VIGIL NEUROSCIENCE, INC.
Profile
Petra Kaufmann is currently the Chief Medical Officer at Affinia Therapeutics, Inc. and Vigil Neuroscience, Inc. She previously worked as the Director-Rare Diseases Research at the National Institutes of Health from 2015 to 2018.
Petra also held positions at Novartis Gene Therapies, Inc., including SVP, Head-Clinical Development & Analytics from 2020 to 2021 and Vice President-R&D Translational Medicine from 2018 to 2020.
She has a graduate degree from The Trustees of Columbia University in The City of New York and a doctorate degree from the University of Bonn.
Petra Kaufmann active positions
Companies | Position | Start |
---|---|---|
VIGIL NEUROSCIENCE, INC. | Chief Tech/Sci/R&D Officer | 19/03/2024 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 31/01/2021 |
Former positions of Petra Kaufmann
Companies | Position | End |
---|---|---|
AVEXIS INC | Chief Tech/Sci/R&D Officer | 31/01/2021 |
AVEXIS INC | Corporate Officer/Principal | 30/04/2020 |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | 31/01/2018 |
Training of Petra Kaufmann
The Trustees of Columbia University in The City of New York | Graduate Degree |
University of Bonn | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
VIGIL NEUROSCIENCE, INC. | Health Technology |
Private companies | 3 |
---|---|
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
- Stock Market
- Insiders
- Petra Kaufmann